Anlotinib Hydrochloride

CAS no.: 1360460-82-7

Type: API

Usage: Lung cancer

Technical description
It is the hydrochloride salt form of catequentinib, a receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic and anti-angiogenic activities. Upon administration, catequentinib targets multiple RTKs, including vascular endothelial growth factor receptor type 2 (VEGFR2) and type 3 (VEGFR3). This agent may both inhibit angiogenesis and halt tumor cell growth.

IUPAC name: 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine;dihydrochloride.

Molecular formula: C₂₃H₂₄Cl₂FN₃O₃

Molecular Weight: 480.4 g/mol

Class: It is a next-generation receptor tyrosine kinase (RTK) inhibitor.

Synonyms: Anlotinib dihydrochloride – Anlotinib hydrochloride – Catequentinib Hydrochloride – CATEQUENTINIB DIHYDROCHLORIDE – UNII-A3749M6582.